July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Crosstalk Between TGFβ2 and TLR4 in the Trabecular Meshwork
Author Affiliations & Notes
  • Amanda L. Roberts
    University of North Texas Health Science Center, Fort Worth, Texas, United States
  • Colleen M McDowell
    University of North Texas Health Science Center, Fort Worth, Texas, United States
  • Footnotes
    Commercial Relationships   Amanda Roberts, None; Colleen McDowell, None
  • Footnotes
    Support  NIH Grant 1R01EY026529, NIH Grant 3R01EY026529-02S1
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4712. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Amanda L. Roberts, Colleen M McDowell; Crosstalk Between TGFβ2 and TLR4 in the Trabecular Meshwork. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4712.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The trabecular meshwork (TM) regulates aqueous humor outflow and intraocular pressure (IOP). The effects of TGFβ signaling pathways on the TM extracellular matrix (EÇM) have been extensively studied. Recently, we identified TGFβ2 and toll-like receptor 4 (TLR4) signaling crosstalk regulates changes in the TM ECM and mutation in Tlr4 rescues TGFβ2 -induced ocular hypertension in mice. Here, we investigated the role of an endogenous TLR4 ligand, FN-EDA, and a downstream signaling molecule of TLR4, NFκB, in TGFβ2 -induced ocular hypertension in mice.

Methods : B6.FN-EDA-/- (n=18), B6.FN-EDA+/+/TLR4-/- (n=7), B6.FN-EDA-/-/ TLR4-/- (n=15), and C57BL/6J (n=11) mice were intravitreally injected with 2.0 μL Ad5.TGFβ2 (2.5x107 pfu) in one eye and the contralateral uninjected eye was used as a negative control. Likewise, we tested mice lacking the p50 subunit of NFκB (B6.Cg-NFκB1tm1Bal/J) (n=7) and C57BL/6J (n=10) mice. IOP was measured using a TonoLab rebound tonometer on isoflurane-anesthetized mice for 42 days post-injection. Significance determined by one-way ANOVA at each time point.

Results : Ad5.TGFβ2 significantly induced ocular hypertension in C57BL/6J mice in both experiments. In the first experimental cohort, Ad5.TGFβ2 significantly induced ocular hypertension in C57BL/6J mice starting at 7-days post injection and remained significant until 42 days post-injection (p<0.0001). IOP peaked at 35 d (Ad5.TGFβ2 injected eye, 21.7 ± 0.5 mmHg; uninjected eye, 13.1 ± 0.2 mmHg; p<0.0001). Mutation in TLR4 and FN-EDA blocked Ad5.TGFβ2 induced ocular hypertension with no significant IOP elevation at any time point. In the second experimental cohort, Ad5.TGFβ2 significantly induced ocular hypertension in C57BL/6J mice starting at 14-days post injection and remained significant until 42 days post-injection (p<0.0001). IOP peaked at 21 d (Ad5.TGFβ2 injected eye, 20.6 ± 0.6 mmHg; uninjected eye, 13.6 ± 0.2 mmHg; p<0.0001). Mutation in NFκB blocked Ad5.TGFβ2 induced ocular hypertension with no significant IOP elevation at any time point.

Conclusions : These findings demonstrate that TLR4, the endogenous TLR4 ligand FN-EDA, and NFκB are necessary for TGFβ2 induced ocular hypertension in mice. These data provide potential new targets to lower IOP and to further explore the molecular mechanisms involved in the development of glaucomatous TM damage.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×